Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 66th Annual Meeting.
[npfButton size=“small” text=”Find out more” href=”https://www.sciencecodex.com/radionuclide-therapy-effective-high-grade-neuroendocrine-neoplasms-628242″ background-colour=”#f06124″ text-colour=”#ffffff”]